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In patients with severe mitral valve regurgitation and
atrial fibrillation, the Cox maze procedure6-10 has not
been used routinely by most surgeons because of the
generally low risk of postoperative thromboembolism
and because of the potential of this additional procedure
to increase the mortality of valve repair. Although sev-
eral authors have reported that atrial fibrillation was
successfully ablated with the Cox maze procedure in
patients undergoing mitral valve procedures,7-10 no data
demonstrate a long-term benefit of reduced late mor-
bidity and mortality associated with the elimination of
atrial fibrillation. We have used the Cox maze proce-
dure in conjunction with valve repair in patients with
severe mitral regurgitation and atrial fibrillation, antici-
pating a low risk of thromboemboli when sinus rhythm
is maintained and the long-term benefit of avoiding
anticoagulation with warfarin. The purpose of this study
was to assess the early- and intermediate-term results of
this combined procedure.
A pproximately 30% to 40% of patients who undergomitral valve repair have chronic atrial fibrillation
before the operation,1-4 and the majority remain in atri-
al fibrillation after the operation. One study reported
that mitral valve repair more than 3 months after the
onset of atrial fibrillation failed to restore normal atrial
contraction.5
Objective: The objective was to determine whether the Cox maze proce-
dure provides adjunctive benefit in patients with atrial fibrillation
undergoing mitral valve repair. Methods: We compared the outcome of
39 patients who had the Cox maze procedure plus mitral valve repair
between January 1993 and December 1996 (maze group) with that of 58
patients with preoperative atrial fibrillation who had mitral valve repair
during the same interval by the same surgeons (control group). Patients
in the 2 cohorts were similar for age, gender, preoperative New York
Heart Association class III or IV, and duration of preoperative atrial fib-
rillation. The control group had a higher incidence of previous heart
surgery and coronary artery disease. Results: No operative deaths
occurred, and 1 patient in each group required pacemaker implantation
after the operation. Duration of cardiopulmonary bypass (122 ± 40 min-
utes vs 58 ± 27 minutes, P < .0001) and hospitalization (12.6 ± 6.4 vs 9.3
± 3.4 days, P < .0025) were prolonged in patients having the Cox maze
procedure. Overall, 2-year survival was similar (92% ± 5% for maze
patients and 96% ± 3% for controls). Freedom from atrial fibrillation in
the maze group was 74% ± 8% 2 years after the operation compared
with 27% ± 7% for the control group (P < .0001). Freedom from stroke
or anticoagulant-associated bleeding in the maze group was 100% 2
years after the operation compared with 90% ± 8% in the control group
(P = .04). At most recent follow-up, 82% of maze patients were in nor-
mal sinus rhythm (53% in control group). Conclusion: The addition of
the Cox maze procedure to mitral valve repair is safe and effective for
selected patients, and elimination of atrial fibrillation decreased late
complications. (J Thorac Cardiovasc Surg 1999;118:628-35)
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Patients and methods
Between January 1993 and December 1996, 97 consecutive
patients with a history of atrial fibrillation underwent mitral
valve repair for mitral regurgitation on 2 hospital services; all
patients had chronic atrial fibrillation or multiple episodes of
paroxysmal atrial fibrillation before the operation. Of the 97
patients, 39 had mitral valve repair with the Cox maze proce-
dure and formed the maze group, and the other 58 had valve
repair alone and formed the control group.
For this study, we retrospectively reviewed and collected
data from operative notes, anesthesia records, clinical case
histories, and laboratory investigations, including electrocar-
diograms, echocardiograms, and cardiac catheterization
reports. Follow-up data were collected from Mayo Clinic
records of outpatient visits and correspondence with patients
and referring physicians. A total of 204 clinical, hemody-
namic, electrocardiographic, and echocardiographic variables
were entered into a computerized database and analyzed.
Follow-up data more than 6 months after the operations were
available for all patients.
Patients. Demographic data and pertinent cardiac informa-
tion are given in Table I. Groups were similar in age, gender
distribution, and New York Heart Association (NYHA) func-
tional class. Similar proportions of patients in each group had
previous myocardial infarction, stroke, rheumatic fever, or
cardioversion. The decision to add the Cox maze procedure
was made by the surgeon; these patients represent the first
group to have combined procedures at our clinic. Eight
patients in the control group had previous heart surgery, but
no patient in the maze group had previous heart surgery (P =
.02). Also, associated coronary artery disease was more fre-
quent in the control group than in the maze group (P = .01).
With respect to preoperative heart rhythm, 80% of patients
in the maze group were in chronic atrial fibrillation, com-
pared with 62% in the control group. The Cox maze proce-
dure was applied to the patients who had multiple episodes of
paroxysmal atrial fibrillation necessitating long-term antico-
agulation before the operation. Three patients in the control
group had a permanent pacemaker inserted at different times
before mitral valve repair. The duration of preoperative
chronic atrial fibrillation was significantly longer in patients
in the maze group than in the control group (45 ± 63 months
vs 28 ± 53 months, P = .03).
Surgical procedure. Methods of mitral valve repair varied
according to the pathologic findings; an annuloplasty ring
was used in almost all patients. The maze III procedure
described by Cox and associates11,12 was used.
Statistical methods. Comparisons of the characteristics
between the 2 patient groups were carried out with c 2 tests or
Fisher’s exact tests for nominal variables, with 2-sample t
tests or Wilcoxon rank sum tests for continuous variables,
and with Wilcoxon rank sum tests for ordinal variables.
Survival and survivorship free of atrial fibrillation, bleeding,
and stroke were estimated by means of the Kaplan-Meier
method. Survivorship curves were compared with the log-
rank test. The relationships of continuous variables to sur-
vivorship and the multivariate relationship of multiple risk
factors to survival were evaluated with the Cox proportional
hazards model.
Results
Pathophysiology of mitral regurgitation and oper-
ative findings. The causes of mitral regurgitation are
summarized in Table II. The most common cause was
mitral valve prolapse with either ruptured chordae or
elongated chordae. More than 50% of patients in both
groups had posterior leaflet repair with either plication
Table I. Comparison of preoperative clinical charac-
teristics of control and maze groups
Control group Maze group 
Variable (n = 58) (n = 39) P value
Male sex, No. (%) 39 (67) 23 (59) .41
Age, mean ± SD (y) 69 ± 19 65 ± 13 .13
NYHA class III or IV, 51 (88) 30 (77) .15
No. (%)
History of rheumatic fever, 4 (7) 6 (15) .19
No. (%)
History of stroke, No. (%) 4 (7) 4 (10) .71
Previous heart surgery, 8 (14) 0 (0) .02
No. (%)
Coronary artery disease (%) 26 (45) 8 (21) .01
History of previous MI, 5 (9) 3 (8) 1.00
No. (%)
History of cardioversion, 6 (10) 4 (10) 1.00
No. (%)
Chronic AF, No. (%) 36 (62) 31 (79) .07
Duration of chronic AF,* 28 ± 53 45 ± 63 .03
mean ± SD (mo)
Duration of chronic AF, 42 ± 62 58 ± 66 .25
mean ± SD (mo)
AF, Atrial fibrillation; MI, myocardial infarction; NYHA, New York Heart
Association; SD, standard deviation.
*Paroxysmal AF is considered as 0 months of chronic AF.
Table II. Comparison of causes of mitral regurgita-
tion in the control and maze groups
Control group Maze group 
(n = 58) (n = 39)
95% 95% 
Cause No. % CI No. % CI
Ruptured chordae 31 53 0-67 10 26 13-42
Prolapse (elongated 11 19 10-31 10 26 13-42
chordae)
Ischemic 5 9 3-19 5 13 4-27
Rheumatic 4 7 2-17 4 10 3-24
Endocarditis 4 7 2-17 4 10 3-24
Other 3 5 1-14 6 15 6-31
CI, Confidence interval.
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or partial resection and suture repair. Anterior leaflet
repairs were undertaken in approximately 25% to 30%
of patients, and posterior ring annuloplasty was used in
almost all patients (95% in the control group and 97%
in the maze group).
Aortic crossclamp time and cardiopulmonary bypass
time were significantly longer in the maze group than
in the control group (aortic crossclamp time, 36 ± 14
minutes vs 69 ± 18 minutes [P < .0001]; cardiopul-
monary bypass time, 58 ± 27 minutes vs 122 ± 40 min-
utes [P < .0001]). Seventy-one percent of patients in the
control group were maintained on normothermic car-
diopulmonary bypass, compared with only 40% of
patients in the maze group (P < .0001).
Associated procedures included coronary artery
bypass grafting (n = 28), repair of atrial septal defects
or patent foramen ovale (n = 14), tricuspid valve repair
(n = 6), pericardiectomy (n = 1), and aortic valve
replacement with tissue valve (n = 1). There was no dif-
ference between the 2 groups in terms of incidence of
associated procedures except that concomitant coro-
nary artery bypass grafting was performed in 7 patients
in the maze group (18%) and 21 patients in the control
group (36%) (P = .05). 
Postoperative morbidity and mortality. No in-hos-
pital deaths occurred in either group. Hospital stay in
the maze group was prolonged compared with that in
the control group (12.6 ± 6.4 days vs 9.3 ± 3.4 days, P
= .003). Postoperative complications included bleeding
(n = 5), respiratory failure (intubation > 72 hours) (n =
2), intra-aortic balloon pump insertion (n = 2), pneu-
monitis (n = 2), pneumothorax (n = 1), and gastroin-
testinal bleeding (n = 1). One patient in each group
required postoperative pacemaker implantation for
junctional bradycardia. There was no difference
between the 2 groups in the incidence of complications.
Survival and late events. All patients were observed
for a minimum of 6 months after the operation. Overall
2-year survival was similar for the 2 groups (maze
group, 92% ± 5%; control group, 96% ± 3%; Fig 1).
There were 7 late deaths. In the maze group, 1 patient
died of congestive heart failure, 1 had ventricular
tachycardia, and another died of an unknown cause. In
the control group, 4 late deaths were due to pulmonary
embolism, intracerebral hemorrhage, cerebral infarc-
tion, and myocardial infarction. Three patients (1 in the
control group, 2 in the maze group) required reopera-
tion for recurrent mitral valve regurgitation (2 patients)
or hemolysis.
Because early postoperative atrial fibrillation may be
caused by mechanisms other than chronic atrial fibril-
lation, we chose to analyze occurrence of the arrhyth-
mia after the first 3 postoperative months. As seen in
Fig 2, freedom from atrial fibrillation in patients in the
maze group was 74% ± 8% 2 years after operation,
compared with 27% ± 7% for patients in the control
group (P < .0001).
There were other significant differences in late events
Fig 1. Actuarial survival analyses. postop, Postoperatively.
Free of event: death P = .90.
Maze group Control group
Survival (No. at risk) Survival (No. at risk)
One year 91.8% ± 4.6% (26) 96.0% ± 2.8% (36)
Two years 91.8% ± 4.6% (15) 96.0% ± 2.8% (22)
Three years 91.8% ± 4.6% (3) 85.9% ± 7.2% (11)
Fig 2. Survival analyses of freedom from recurrent atrial fib-
rillation starting at 3 months after operation. fib, Fibrillation;
postop, postoperatively. Free of event: atrial fibrillation
P < .001.
Maze group Control group
Survival (No. at risk) Survival (No. at risk)
Three months 94.7% ± 3.6% (35) 46.6% ± 6.5% (27)
One year 81.5% ± 6.9% (21) 41.2% ± 6.5% (18)
Two years 73.5% ± 8.2% (12) 26.3% ± 6.5% (8)
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between the 2 groups. Late complications of bleeding
and stroke were fewer in the maze group. In the maze
group, no patient had a stroke, and 1 patient who did
not receive anticoagulation treatment with warfarin had
a hemorrhagic complication. In contrast, in the control
group, 4 patients had strokes and 4 had bleeding (1
event not associated with warfarin).
Freedom from stroke and bleeding at 2 years was 95%
± 5% in the maze group and 86% ± 6% in the control
group (P = .08). If we consider only bleeding associated
with warfarin treatment, freedom from combined stroke
and bleeding at 2 years was 100% in the maze group and
90% ± 8% in the control group (P = .04; Fig 3).
Electrocardiogram. At the time of hospital dismissal,
95% of patients in the maze group were free of atrial fib-
rillation, compared with 50% of those in the control
group (Table III). At dismissal, 10 patients had junction-
al rhythm, 9 of them in the maze group. Of these 9
patients, 4 later converted to normal sinus rhythm, 2 to
atrial fibrillation, and 2 to atrial flutter; the 1 other
patient had pacemaker placement during hospitalization
and was still in junctional rhythm at follow-up.
With the most recent electrocardiogram, 82% of
patients in the maze group were in normal sinus
rhythm, compared with 53% in the control group. Of
note, 77% of patients with preoperative chronic atrial
fibrillation converted to normal sinus rhythm after the
Cox maze procedure, compared with only 31% of those
in the control group.
The relationship between return of sinus rhythm and
duration of preoperative atrial fibrillation is shown in
Table IV. Only 18.5% of patients in the control group
Fig 3. Survival analyses of freedom from combined stroke and anticoagulant-related bleeding. postop, Postopera-
tively. Free of event: stroke or anticoagulant-related bleeding P = .04.
Maze group Control group
Survival (No. at risk) Survival (No. at risk)
One year 100.0% ± 0.0% (26) 94.0% ± 3.4% (35)
Two years 100.0% ± 0.0% (15) 90.1% ± 5.0% (21)
Table III. Comparison of heart rhythm in the control and maze groups
Dismissal Most recent
Control group Maze group Control group Maze group 
(n = 58) (n = 39) (n = 58) (n = 39)
Rhythm No. % No. % No. % No. %
Normal sinus 25 43 28 72 31 53 32* 82
Atrial flutter 3 5 0 0 1 2 2 5
Atrial fibrillation 24 41 2 5 21 36 4 10
Junctional 1 2 9 23 0 0 1 3
Pacemaker rhythm with 5 9 0 0 5 9 0 0
underlying atrial fibrillation
Proportion of atrial fibrillation at dismissal is significantly different between control group and maze group (P < .001).
*Includes 1 patient with ectopic atrial rhythm.
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who had chronic atrial fibrillation more than 3 months
regained normal sinus rhythm. In the maze group, 76%
of patients who had chronic atrial fibrillation longer
than 3 months regained normal sinus rhythm (Table IV).
Risk factors for recurrence of atrial fibrillation.
Risk factors for recurrence of atrial fibrillation were
assessed by univariable analysis (Table V). Omission of
a Cox maze procedure, larger preoperative left atrial
dimension, and chronic atrial fibrillation were signifi-
cant risk factors for recurrence of atrial fibrillation.
Multivariable analysis, however, demonstrated that
only omission of the Cox maze procedure (P = .0007)
and chronic atrial fibrillation (P = .03) were indepen-
dent risk factors for recurrence of atrial fibrillation
(Table VI). Preoperative left atrial dimension was not
associated with recurrence of atrial fibrillation (P =
.14). On the basis of these results, we constructed sur-
vival curves of freedom from recurrent atrial fibrilla-
tion stratified by type of atrial fibrillation (paroxysmal
versus chronic) and maze versus control (Fig 4).
Patients with preoperative paroxysmal atrial fibrillation
who had the Cox maze procedure were completely free
of recurrent atrial fibrillation.
Antiarrhythmic drugs and warfarin. We routinely
resumed treatment with most antiarrhythmic agents
prescribed before the operation for a period of 6 to 8
weeks after the operation, and warfarin also was pre-
scribed routinely for 3 to 6 months after mitral valve
repair. Decisions about use of medications were super-
vised by the local attending cardiologist or general
physician.
The spectrum and intensity of preoperative antiar-
rhythmic therapy were comparable for the 2 groups,
but after operation, the number of antiarrhythmic drugs
decreased over time in the maze group from 1.31 ±
0.69 to 0.71 ± 0.76 at follow-up, compared with 1.26 ±
0.78 to 1.16 ± 0.79 for the control group (P = .01). In
the maze group, 45% of patients were free of all antiar-
rhythmic agents at most recent follow-up, compared
with 22% in the control group (P = .02).
With respect to warfarin, 63% of patients in the maze
group were not taking warfarin compared with 50% in
the control group, but this difference did not reach sta-
tistical significance. However, 9 patients (23%) who
had no episodes of atrial fibrillation after surgery are
still taking warfarin, and the drug presumably may be
safely discontinued. In addition, 5 patients in the con-
trol group who had a permanent pacemaker for pro-
found bradycardia with underlying atrial fibrillation
stopped taking warfarin.
Table IV. Comparison of restoration of normal sinus rhythm in the control and maze groups
Control group (n = 58) Maze group (n = 39)
Duration of No. of No. in No. of No. in 
preoperative AF patients NSR % patients NSR %
Paroxysmal AF 22 20 91 8 8 100
Chronic AF
≤3 mo 7 4 57 4 3 75
4-12 mo 7 1 14 5 4 80
12 mo 20 4 20 20 15 75
Unknown 2 2 100 2 2 100
AF, Atrial fibrillation; NSR, normal sinus rhythm.
Table V. Results of univariable analysis of risk factors
for recurrence of atrial fibrillation
Variable P value Hazard ratio 95% CI
No Cox maze procedure <.00001 4.27 2.07, 8.85
Preoperative left atrial .01 1.05 1.01, 1.10
dimension
Chronic atrial fibrillation .05 2.01 1.03, 4.03
MR on most recent .054 1.71 0.96, 3.03
echocardiogram
Gender .32 1.37 0.75, 2.48
Preoperative ejection .40 0.99 0.96, 1.02
fraction
TR on most recent .41 1.28 0.72, 2.29
echocardiogram
Duration of chronic .65 1.00 1.00, 1.01
atrial fibrillation
CI, Confidence interval; MR, mitral regurgitation; TR, tricuspid regurgitation.
Table VI. Results of multivariable analysis of risk
factors for recurrence of atrial fibrillation
Variable P value Hazard ratio 95% CI
No Cox maze procedure .0007 4.4 1.9, 10.5
Chronic atrial fibrillation .03 3.3 1.1, 9.8
Preoperative left atrial .14 1.0 1.0, 1.1
dimension
CI, Confidence interval.
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Discussion
The Cox maze procedure was designed to prevent
reentrant atrial fibrillation,13 and several series have
confirmed the success of the operation.6,14 As a result,
indications have been extended from lone atrial fibril-
lation to treatment of atrial fibrillation in patients hav-
ing cardiac surgery for associated mitral valve disease,
atrial septal defect, or other organic cardiac disease.8-11
The restoration of normal sinus rhythm brings symp-
tomatic relief of palpitation and better atrial transport
function.4 However, the most important potential bene-
fit of the Cox maze procedure is reduction in risks
of thromboembolism and anticoagulant-associated
bleeding.
Atrial fibrillation is prevalent among patients referred
for operations on the mitral valve; previous studies
have shown that approximately 30% to 40% of patients
were in chronic atrial fibrillation when mitral valve
repair was scheduled.1-5 In our experience, approxi-
mately 80% of the patients who had preoperative
chronic atrial fibrillation more than 3 months before the
operation remained in atrial fibrillation after successful
mitral valve repair.5 In the present investigation, the
adjunctive Cox maze procedure increased the restora-
tion of normal sinus rhythm to 82% of patients, a find-
ing similar to that of other studies.8-10 Furthermore, our
data suggest that concomitant Cox maze procedure
reduced the combined risks of stroke and anticoagu-
lant-related bleeding, as well as decreased the need for
antiarrhythmic drugs.
Risks of stroke in nonrheumatic atrial fibrillation
have been studied extensively in regard to primary
prevention15-18 and secondary prevention.19,20 Recent
prospective studies have shown that the risk of stroke in
placebo-treated patients with atrial fibrillation is 5% to
8% per year.15,16,18 The reduction in risk of stroke by
anticoagulation with warfarin ranges from 37% to
86%, but chronic anticoagulation with warfarin carries
a risk of bleeding from 0.5% to 2.8% per year.21,22
Furthermore, anticoagulation with warfarin requires
careful follow-up and adjustment of dosage; use of a
low dose of warfarin and aspirin without monitoring
Fig 4. Survival analyses of freedom from recurrent atrial fibrillation starting 3 months after operation stratified
by type of atrial fibrillation (chronic vs paroxysmal) and Cox maze procedure (maze vs control). fib, Fibrillation.
Free of event: atrial fibrillation. 
Paroxysmal—maze group Paroxysmal—control group
Survival (No. at risk) Survival (No. at risk)
Three months 100.0% ± 0.0% (35) 77.3% ± 8.9% (17)
One year 100.0% ± 0.0% (21) 68.2% ± 9.9% (12)
Two years 100.0% ± 0.0% (12) 46.9% ± 1.3% (5)
Chronic—maze group Chronic—control group
Survival (No. at risk) Survival (No. at risk)
Three months 93.3% ± 4.6% (27) 27.8% ± 7.5% (26)
One year 78.1% ± 8.0% (18) 24.7% ± 7.2% (6)
Two years 73.5% ± 8.2% (12) 12.3% ± 6.2% (3)
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the international normalized ratio is not as effective as
conventional anticoagulation with warfarin.23
Maintenance of sinus rhythm and avoidance of anti-
coagulation with warfarin may reduce medical expens-
es; long-term anticoagulation with warfarin is estimat-
ed to cost about $800 per person annually in the United
States.24 Medical expenditures for care of patients with
stroke or bleeding also are substantial.24 In the early
results of the present study with 21 months of mean
follow-up, about 36% of patients in the maze group
(50% in the control group) were still taking warfarin.
We expect that the majority of patients in the maze
group who are in sinus rhythm eventually will discon-
tinue taking warfarin.
An additional benefit of concomitant Cox maze pro-
cedure for restoration of sinus rhythm is reduced need
for antiarrhythmic agents. The results of the Cardiac
Arrhythmia Suppression Test (CAST) study and other
clinical trials suggested that antiarrhythmic agents
commonly used for atrial fibrillation, such as quinidine
and amiodarone, have proarrhythmic effects.25-27 After
the Cox maze procedure, the number of antiarrhythmic
drugs was decreased, and 44% of patients were free of
antiarrhythmic therapy.
The major limitation of our study is that it was not
randomized, and there were some differences in the
baseline characteristics of patients in the 2 groups. The
decision for or against an adjunctive Cox maze proce-
dure reflected the surgeon’s experience with the proce-
dure, as well as the anticipated difficulty with mitral
valve repair. With experience, however, we rarely
decided against a concomitant Cox maze procedure on
the basis of the planned operation; more often, local
factors such as extreme fragility of tissue, unusual
bleeding, or poor exposure militated against a con-
comitant maze procedure. Selection bias is reflected by
the absence of patients with previous cardiac opera-
tions and coronary artery disease in the maze group.
However, we do not consider previous heart surgery
alone to be a contraindication to the procedure and
have successfully performed the Cox maze procedure
in several patients having second or third procedures.
Of interest, the duration of preoperative atrial fibril-
lation was longer in the maze group than in the control
group, and the proportion of patients in chronic atrial
fibrillation was also greater; these factors would be
expected to increase the risk of late atrial fibrillation.
Among patients in the control group who had chronic
atrial fibrillation more than 3 months, only 18.5% had
a return of sinus rhythm (Table IV). In the maze group,
76% of patients who had chronic atrial fibrillation
longer than 3 months regained normal sinus rhythm.
Thus the addition of the Cox maze procedure appears
to be particularly useful in patients with chronic atrial
fibrillation of more than 3 months’ duration. Of note,
survival free of recurrent atrial fibrillation in a control
group with paroxysmal atrial fibrillation was only 49%
± 1% at 2 years (Fig 4). The complete suppression of
paroxysmal atrial fibrillation with the Cox maze proce-
dure in this study suggests that the combined operation
may be of benefit for patients who have multiple
episodes of paroxysmal atrial fibrillation necessitating
long-term anticoagulation before mitral valve repair.
Some groups have advocated only the left-sided inci-
sions to ablate atrial fibrillation in patients having
mitral valve repair or replacement to reduce morbidity
and mortality.28 In our series, there was little difference
in either survival or perioperative morbidity between
patients having valve repair with and those having
valve repair without concomitant maze procedure, and
it is unlikely that limiting the incisions to the left atri-
um would have influenced the clinical results.
Reduction of left atrial size by resection of atrial
muscle at the time of the Cox maze procedure has been
described.7 However, multivariable analysis of our data
did not confirm that preoperative left atrial size was
predictive of recurrence of atrial fibrillation. Therefore
the role of additional resection to reduce atrial size dur-
ing the Cox maze procedure is questionable.
Although 9 patients who had the Cox maze proce-
dure were in junctional rhythm at the time of hospital
dismissal, only 1 required a permanent pacemaker and
4 of the 9 had return of sinus rhythm. In the experience
at Barnes Hospital, 25% of patients who had the Cox
maze procedure required permanent pacemaker place-
ment.29 Persistent junctional rhythm may indicate long-
standing sinus node dysfunction and, certainly, this
predisposes patients to reentrant atrial arrhythmias and
stroke.30 Among the other 4 patients with junctional
rhythm at dismissal, recurrent atrial fibrillation devel-
oped in 2 and atrial flutter in 2. It has been reported that
up to 50 weeks are required until normal sinus rhythm
is restored.7 Theophylline therapy was proposed for
early sinus node dysfunction with slow junctional
rhythm after the Cox maze procedure,7 but we have not
used this.
Our experience suggests that the Cox maze operation
is a safe and reliable adjunctive procedure for selected
patients with atrial fibrillation undergoing mitral valve
repair. It seems particularly useful for patients with
chronic atrial fibrillation of more than 3 months’ dura-
tion before the operation. Perioperative morbidity and
mortality are very low. Early follow-up documents
restoration of sinus rhythm in more than 75% of
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patients and reduced risks of thromboembolism and
bleeding due to warfarin. Although the addition of the
Cox maze procedure lengthens hospital stay in patients
having mitral valve repair, overall medical costs may be
decreased by reducing the need for long-term anticoag-
ulation, as well as costs associated with stroke and
bleeding complications.
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